Form 4: Viridian CFO Harmon Reports Equity Grants, Stock Activity

Viridian Therapeutics' Chief Financial Officer, Seth Harmon, reported new equity grants including stock options and restricted stock units, alongside the vesting and tax-related disposition of common stock.

Summary

• Seth Harmon, Chief Financial Officer of Viridian Therapeutics, Inc., reported several equity transactions.
• On March 2, 2026, Harmon was granted stock options to purchase 102,850 shares of common stock at an exercise price of $30.25 per share, vesting in 48 equal monthly installments.
• Also on March 2, 2026, Harmon received a grant of 20,550 Restricted Stock Units (RSUs), which vest over a four-year period, with 25% vesting on each yearly anniversary of the grant date.
• On March 3, 2026, 6,267 shares of common stock were acquired due to the vesting of previously granted RSUs.
• Concurrently, 2,091 shares of common stock were disposed of at a price of $29.32 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Harmon directly beneficially owns 7,790 shares of common stock, 102,850 stock options, and 18,801 Restricted Stock Units.
• The reported beneficial ownership also includes 903 shares acquired on March 17, 2025, and 1,000 shares acquired on September 17, 2025, through the company's Employee Stock Purchase Plans.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting ongoing executive compensation and retention efforts through equity grants, which aligns management incentives with long-term company performance. The disposition of shares is solely for tax purposes, a standard practice.

Positives

• Chief Financial Officer Seth Harmon received a grant of 102,850 stock options, indicating continued alignment of management incentives with shareholder value.
• Harmon was granted 20,550 Restricted Stock Units, further increasing his equity stake and long-term commitment to the company.
• The acquisition of 6,267 shares of common stock through RSU vesting demonstrates the realization of previously granted equity compensation.

Negatives

• 2,091 shares of common stock were disposed of at $29.32 per share to cover tax withholding obligations, representing a reduction in direct common stock ownership.

Industry Context

StockSavvy.ai notes that equity grants to executive officers like the CFO are standard practice in the biotechnology and pharmaceutical industries, serving to align management's long-term interests with those of shareholders and to incentivize performance. The vesting schedules for both options and RSUs are typical for retaining key talent in competitive sectors.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's interests with shareholders, potentially fostering long-term value creation.
• Employees: The existence of an Employee Stock Purchase Plan (ESPP) mentioned in the filing indicates broader employee equity participation opportunities.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, including grants of stock options and restricted stock units, and the subsequent vesting and tax-related sale of shares. Such transactions are standard practice for executive compensation and do not typically indicate a fundamental change in the company's prospects or warrant a change in investment recommendation based solely on this filing. The grants align management incentives with long-term shareholder value, which is generally positive, but the overall impact on the stock's valuation is neutral given its routine nature.

Keywords

Viridian Therapeutics, VRDN, Seth Harmon, Chief Financial Officer, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Beneficial Ownership